IngredientsIsobutylamides — also written as N-isobutylamides, and often discussed under the broader class term alkylamides (or alkamides) — are a structurally related family of naturally occurring fatty acid amides. Natural alkylamides are constituted by an aliphatic, cyclic or aromatic amine residue (R₁) and a C8 to C18 saturated or unsaturated chain acid, which can also be aromatic (R₂). The defining structural feature of the isobutylamide sub-class is that the amine head group is specifically isobutylamine (2-methylpropylamine), meaning the nitrogen bears a branched four-carbon group. The acid moiety attached to this amine head is typically a long-chain, polyunsaturated fatty acid, creating a conjugated system with characteristic geometry (commonly combinations of E and Z double bonds, and/or acetylenic linkages).
They are also classified as protoalkaloid or pseudoalkaloid compounds and represent a group of lipidic compounds structurally related to animal endocannabinoids and are strongly active metabolites in the central nervous system.
Among the best-characterized isobutylamides are:
Alkylamides are a broad and expanding group of bioactive natural compounds grouped in at least 33 plant families including Aristolochiaceae, Asteraceae, Brassicaceae, Convolvulaceae, Euphorbiaceae, Menispermaceae, Piperaceae, Poaceae, Rutaceae and Solanaceae. Within these families, the isobutylamide sub-class is especially concentrated in the genera Echinacea, Acmella/Spilanthes, Heliopsis, Anacyclus, Zanthoxylum, and Piper.
Echinacea spp. (Purple Coneflower) — Asteraceae
Echinacea alkylamides are represented by the isomers of 2,4,8,10-dodecatetraenoic acid isobutylamide; a diversity of alkylamides in Echinacea are similarly isobutylamides with alkyl chains of variable length and saturation. Three species are commercially important: E. purpurea, E. angustifolia, and E. pallida, and their isobutylamide profiles differ. Amide 1 (a monoene isobutylamide) is a significant constituent of E. purpurea, whereas diacetylenic amides are found in E. angustifolia. A complex mixture containing at least 12 different acetylenic amides can be obtained by supercritical fluid extraction of fresh dried roots of E. angustifolia.
Acmella oleracea (Jambu / Paracress) and Spilanthes acmella — Asteraceae
Spilanthol (C₁₄H₂₃NO, 221.339 g/mol) is a bioactive compound found in many different plants used as traditional remedies throughout the world. It is present in Heliopsis longipes and several species in the genus Acmella, including A. oleracea L., also known as paracress and jambu. Eleven N-alkylamides — namely eight N-isobutylamides, two 2-methylbutylamides and one 2-phenylethylamide — were isolated and identified from ethanolic Spilanthes extracts by HPLC/ESI-MS and LC-MS methods.
Heliopsis longipes (Chilcuague / Aztec Root) — Asteraceae
Heliopsis longipes (A. Gray) S.F. Blake (Asteraceae) is an herbaceous plant native to Mexico, growing particularly in the states of Querétaro, Guanajuato, and San Luis Potosí, where it is known by common names including "Chilcuague," "Chilcuán," "Chilmecatl," "Aztec root," and "Golden root." In Central Mexico, the roots of this species are widely used as a spice, home insecticide, and for the treatment of some illnesses, including toothaches, gingival disease, and muscular pain. The predominant bioactive molecules found in H. longipes roots are N-alkylamides or alkamides, mainly N-isobutyl-2E,6Z,8E-decatrienamide, also known as affinin or spilanthol.
Zanthoxylum spp. (Szechuan/Sichuan Pepper, Prickly Ash) — Rutaceae
Zanthoxylum species have long been utilized in traditional medicine; among their various properties, they provide an analgesic effect. Central to this medicinal application are alkamides, a class of alkaloids characterized by their unsaturated fatty acid chains. These compounds are particularly noted for their distinctive alleviation of tingling and numbing effects, which are beneficial in dental pain management and local anesthesia. Ten unsaturated alkylamides were isolated from the pericarps of Zanthoxylum bungeanum.
Piper nigrum / Piper longum (Black/Long Pepper) — Piperaceae
An extract of black pepper (Piper nigrum) exhibited strong insecticidal activities against several insects. From the extract, an amide, N-isobutyl-11-(3,4-methylenedioxyphenyl)-(2E,4E,10E)-2,4,10-undecatrienamide (pipercide) and two structurally related amides were isolated as insecticidal principles. Long-chain polyunsaturated isobutylamides from species of Piperaceae, Asteraceae, and Rutaceae have long been recognized as having insect toxicity.
Anacyclus pyrethrum (Pellitory Root) — Asteraceae
Pellitorine, the isobutylamide isolated first historically from this species, is chemically N-isobutyl-2E,4E-decadienamide. Trans-pellitorine ((E,E)-2,4-decadienoic acid N-isobutylamide) shows mainly mouth-watering activity without a strong tingling effect.
Isobutylamides reach consumers primarily in the context of their parent plant preparations. For Echinacea, these include ethanolic tinctures and expressed juice (standardized by isobutylamide content), tablets, capsules, lozenges, and soft-gel capsules. Lipophilic (ethanolic) extractions are required to adequately concentrate these lipid-soluble compounds, and aqueous preparations (teas, water extracts) contain little or no isobutylamide content. Echinaforce, a well-studied commercial product, is prepared by alcoholic (57.3% m/m) extraction from freshly harvested E. purpurea with a combination of 95% herba (DER = 1:12) and 5% roots (DER = 1:11). For Acmella/Spilanthes, supercritical CO₂ extraction and oleoresin preparations concentrate spilanthol/isobutylamide content. Heliopsis longipes roots are used fresh, dried, or in dichloromethane/ethanolic extracts. In the food industry, the leaves and flowers of A. oleracea have sensory properties (pungency, tingling, numbing, mouth-watering) that make it a popular spice and ingredient in several Brazilian dishes.
Echinacea is perhaps the best known medicinal plant of North America and has a long and rich cultural history of use. Classic ethnopharmacology research on echinacea has focused mainly on activities such as antimicrobial action and immunomodulation in relation to traditional pharmacopoeial uses for colds and flu. These uses find their origin in the practices of 19th-century Eclectic physicians who borrowed knowledge of indigenous peoples of the prairies (Great Plains) of North America. Echinacea spp. were also used extensively by indigenous cultures for management of pain, for example toothache by the Niitsitapi (Blackfoot First Nation), arthritis by the Tsestho'e (Cheyenne tribes), and rheumatism or burns by the Šakówiŋ (Dakota and Lakota First Nations). Currently popular as an immune stimulant, Echinacea species were used by North American Indigenous Peoples as a treatment for throat infections, wounds and pain, and was historically used in Eclectic medicine for septic conditions. The tingling sensation produced when tinctures or roots were chewed was historically recognized as a quality marker, directly attributable to the isobutylamide content.
Heliopsis longipes is a Mexican plant that was used by the Náhuatl civilization as a flavoring in the food preparation. Its root is used as a condiment in sauces and spicy meals because it has a flavor similar to chili; in addition, it is used in traditional medicine to alleviate tooth and muscle pains, and also as an insecticide. When H. longipes roots come into contact with oral cavity tissues, they produce numbness and a tingling sensation of the tongue, associated with a significant increase in salivary flow.
Two natural alkylamides, α-hydroxy-sanshool and spilanthol, are found in Szechuan pepper (Xanthoxylum piperitum) and Jambu fruit (Acmella oleracea), respectively, and are used in ethnic cuisines to provide unique oral sensations during the consumption of meals. Medicinal uses of these compounds have also been described; the plants have been used indigenously as analgesics, digestive aids and are purported to stimulate immune responses. The bark of Zanthoxylum integrifoliolum is used by Ya-Mei aborigines as a folk medicine to treat snakebites.
Spilanthes acmella is used in traditional medicine throughout Asia and South America, where it is known as Jambu. The leaves are used for culinary purposes, and the flowers have been used for their numbing and pain-relieving properties, earning the plant such common names as the toothache plant. It has been noted to relieve stomatitis, have taste-activating properties, and to induce a salivary response. Additional traditional uses documented in the literature include treatment for rheumatism, as a sialagogue for stammering, tongue paralysis, antipyretic, sore throat, and gum infections.
Different classes of secondary metabolites of Echinacea, such as alkylamides, caffeic acid derivatives, polysaccharides, flavonoids, and glycoproteins, are believed to be biologically and pharmacologically active. Among these, isobutylamides are unique in being bioavailable orally. Among the phytochemicals found in Echinacea, the bioavailable alkylamides are thought to be the compounds responsible for its effects on the human immune system.
The most extensively characterized molecular mechanism of isobutylamides — particularly those from Echinacea — is agonism at endocannabinoid receptors. Echinacea alkylamides demonstrate multi-target behaviour: nanomolar-affinity CB₂ activation dampens TNF-α and IL-6, whereas partial TLR4 antagonism re-balances Th1/Th2 cytokine bias, potentially complementing conventional immunosuppression. Woelkart et al. (2006) reported that alkylamides exhibited selective affinity to CB2 receptors and can therefore be considered CB ligands. The study also suggested that CB2 interactions may be the molecular mode of action of Echinacea alkylamides as immunomodulators.
Recent research has revealed a relevant new mechanism of pain management by echinacea mediated by alkylamides (AKA) acting at the cannabinoid (CB) receptors. In addition to selectively binding and activating CB2 receptors, certain echinacea alkylamides (AKA) can modulate endocannabinoid system (ECS) activity through effects on endocannabinoid metabolism and transport.
It has been demonstrated that the pharmacological activity of lipophilic Echinacea extracts is attributable to isobutylamides, ligands of the CB1 and CB2 cannabinoid receptors. Isobutylamides possess immunostimulating activity which characterises the traditional and pharmaceutical use of Echinacea extracts.
At nanomolar concentrations, specific alkylamides and also the non-CB2-binding alkylamide undeca-2E-ene,8,10-diynoic acid isobutylamide all significantly inhibited lipopolysaccharide-induced tumor necrosis factor alpha, IL-1beta, and IL-12p70 expression in a CB2-independent manner. This indicates that isobutylamides act through multiple parallel pathways in immune modulation. Overall, alkylamides potently inhibited lipopolysaccharide-induced inflammation in human whole blood and exerted modulatory effects on cytokine expression, but these effects are not exclusively related to CB2 binding.
Specific isobutylamide isomers show different immunological profiles. Among the tetraenoic acid derivatives, dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (AKA9) and its 10E isomer dodeca-2E,4E,8Z,10E-tetraenoic acid isobutylamide (AKA10) demonstrate markedly different activities.
Although previous research suggests that the alkylamides present in Echinacea may be responsible for reducing the symptoms associated with the common cold or flu through their immunomodulatory activity, the roles of specific alkylamides and their targets have not been well-elucidated or established. One study found that the specific alkylamide Dodeca-2E,4E-Dienoic acid isobutylamide had potent antiviral activity against rhinovirus (the causative agent of most common colds) and influenza virus, as well as potent inhibition of IL-8 cytokine production.
Alkylamides are a unique class of compounds that elicit a distinctive tingling sensation when applied to mucosal surfaces. This sensory effect is mechanistically distinct from capsaicin. Prior treatment with the TRPV1 or TRPA1 agonists, capsaicin and mustard oil, did not cross-desensitize the tingle sensation evoked by isobutylamide, suggesting that neither TRPV1 nor TRPA1 participate in the transduction mechanism sub-serving tingle. Other foodborne activators of TRPA1 are found in the family of alkylamides, such as the non-specific agonist of TRPV1, hydroxy-α-sanshool, from Szechuan pepper.
Affinin (spilanthol) is the main bioactive alkylamide present in Heliopsis longipes roots, exerting antinociceptive and anti-inflammatory effects that involve the activation of TRP channels.
Through a bioassay-directed separation, affinin was the unique active compound, evoking GABA release 0.5 minutes after administration at 1×10⁻⁴ M concentration in isolated brain slice studies, suggesting a GABAergic contribution to its analgesic effects.
Cytochrome P450 enzymes (P450s) appear to be the principal system responsible for the metabolism of Echinacea components and most of the main hepatic and some extrahepatic isoforms appear to be involved. Epoxide formation, N-dealkylation and hydroxylation are the main metabolic pathways mediated by P450s. Interactions with P450s determine the circulating concentrations and duration of action of these phytochemicals as well as any potential interactions with other chemicals.
Recently, many new insights concerning the molecular mode of action of the main lipophilic constituents, the alkamides, have renewed interest in this plant. In order to compare the bioavailability of alkamides from liquid and tablet preparations of E. purpurea (Echinaforce) in humans and to study the effects on ex vivo stimulated blood cells, a randomized, single-dose, crossover study with 10 (8 test, 2 placebo) volunteers was performed. Both doses (liquid and tablet) contained the same amount (0.07 mg) of the major alkamides, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides.
Background: Echinacea preparations are one of the best-selling herbal medicinal products with a well-established therapeutic use in the prophylaxis of upper respiratory tract infections. Their consumption is increasing.
In vitro and preclinical evidence: An Echinacea purpurea extract and the alkylamide dodeca-2E,4E-dienoic acid isobutylamide were found to inhibit mast cell degranulation and calcium influx. Echinacea spp. produce many fatty acid amides referred to as alkylamides, which can inhibit cytokine, chemokine, and prostaglandin production from macrophages and T cells. Alkylamides are thought to contribute to the anti-inflammatory activity of E. purpurea extracts by inhibiting production of inflammatory mediators.
Human pharmacokinetic evidence: Alkylamides are a group of active components of the widely used herb Echinacea purpurea, which have immunostimulatory and anti-inflammatory effects. For the most abundant alkylamides, dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides (DTAI), an LC-MS/MS assay has been developed and validated for quantification in human plasma.
Randomized controlled trial (prevention): A large double-blind, placebo-controlled trial investigated E. purpurea standardized to contain 5 mg/100 g of dodecatetraenoic acid isobutylamide. Echinacea reduced the total number of cold episodes, cumulated episode days within the group, and painkiller-medicated episodes. Echinacea inhibited virally confirmed colds and especially prevented enveloped virus infections (P < 0.05). Echinacea showed maximal effects on recurrent infections, and preventive effects increased with therapy compliance and adherence to the protocol.
Randomized controlled trials (treatment — negative/mixed results): A well-known randomized controlled trial published in Annals of Internal Medicine found that no statistically significant differences were detected between the echinacea and placebo groups for any of the measured outcomes. The formulation used in that trial was analytically verified to contain 0.42% dodecatetraenoic acid isobutylamide by weight. Another large RCT assessed cold severity using the Wisconsin Upper Respiratory Symptom Survey, with the primary outcome being the area under the curve for global severity, with severity assessed twice daily by self-report.
Synthesis of evidence strength: Despite its worldwide acceptance, only limited data are available on its prophylactic efficacy. Long-term clinical trials studying spontaneous colds reported mixed results. Overall, the clinical evidence for isobutylamide-containing Echinacea preparations in respiratory infections is mixed: some standardized preparations show statistically significant preventive benefits while others do not, and results depend substantially on product standardization, dose, and timing of use. The roles of specific alkylamides and their targets (immune and/or antiviral) have not been well-elucidated or established in human populations. Evidence is therefore considered preliminary to moderate for prevention, and mixed for treatment.
Traditional basis: As described in Section 2, isobutylamide-rich plants have been used for toothache relief across multiple unrelated cultural traditions (North American, Mexican, South American, Asian). Alkamide extracts or whole plants rich in alkamides are used in the treatment of toothaches or as anesthetics.
Preclinical evidence (Heliopsis/spilanthol): H. longipes extract and affinin demonstrated antinociceptive effect, modified anxiety behavior, and prolonged the time of sodium pentobarbital-induced hypnosis. Affinin elicited these activities at high doses. Previous studies have shown that affinin, the major alkamide of H. longipes roots, induces potent antinociceptive and anti-inflammatory activities.
Preclinical evidence (Echinacea): In an inflammatory pain model, oral administration of either E. angustifolia or E. purpurea root extract produced dose-dependent analgesic effects that were partially reversed by co-administration of CB receptor antagonists. Suppression of inflammatory pain was partially blocked by CB2 antagonist AM630 for both species, and by CB1 antagonist AM251 for E. angustifolia root extract. Whereas CB2 antagonism reduced the effects of both extracts to a similar degree, activation of CB1 appears to account for the stronger analgesic response to E. angustifolia relative to E. purpurea. Accordingly, while activation of peripheral CB2 receptors contributed strongly to the analgesic effects of both extracts (likely by reducing inflammation), E. angustifolia may also act on central CB1 receptors and offer greater therapeutic potential.
Human data: Human data on analgesic applications of spilanthol/isobutylamides are largely lacking. A comprehensive review synthesizing the existing phytochemical research on alkamides derived from 11 Zanthoxylum species focused on their chemical properties, pharmacodynamics, and clinical implications. The analysis includes examination of structure-activity relationships, pharmacokinetics, and mechanisms by which these compounds modulate sensations such as pungency and numbness, contributing to their analgesic and local anesthetic efficacy. Evidence in humans is currently largely anecdotal or derived from sensory pharmacology studies; robust clinical trials are lacking. Evidence strength: preclinical / preliminary in humans.
In vitro evidence: A 2025 study tested the antiviral and cytokine regulatory activity of various specific alkylamides present predominantly in Echinacea root extracts and found that one specific alkylamide, Dodeca-2E,4E-Dienoic acid isobutylamide, had potent antiviral activity against rhinovirus (the causative agent of most common colds) and influenza virus, as well as potent inhibition of IL-8 cytokine production.
While these in vitro findings are mechanistically informative, they have not yet been translated into dedicated human clinical trials testing antiviral isobutylamide doses directly. Evidence strength: in vitro only; not yet established in humans.
In vitro and animal studies suggest that Spilanthes, related species, and their compounds have antimicrobial, antinociceptive, anti-inflammatory, gastroprotective, and taste-activating properties. Spilanthol can exert a variety of biological and pharmacological effects including analgesic, neuroprotective, antioxidant, antimutagenic, anti-cancer, anti-inflammatory, antimicrobial, antilarvicidal and insecticidal activities. Literature surveys suggest multiple pharmacological actions for Spilanthes acmella including antifungal, antipyretic, local anaesthetic, bioinsecticide, anticonvulsant, antioxidant, analgesic, antimicrobial, antinociception, diuretic, vasorelaxant, and anti-inflammatory effects. Human clinical evidence specifically targeting isobutylamides for inflammation is absent; nearly all data are in vitro or in animal models. Evidence strength: preclinical only.
Amides from pepper plants exhibited notable paralyzing effects and lethal activity against susceptible and pyrethroid-resistant insects. Electrophysiological studies using the central nerve cord of the American cockroach demonstrated that these amides are neurotoxic. Larvicidal structure-activity studies show that the N-isobutylamine moiety might play a crucial role in the larvicidal activity. Additionally, the traditional medicine Spilanthes acmella, and the alkylamides spilanthol and undeca-2e-ene-8,10-diynoic acid isobutylamide, demonstrated in vitro and in vivo antimalarial activity. These findings are of scientific and potential public health interest but are not directly relevant to dietary supplementation in humans.
Dichloromethane and ethanolic extracts of H. longipes roots, and affinin isolated from these roots, produce a concentration-dependent vasodilation of rat aorta. This is an animal-only finding with no established clinical application. Evidence strength: preclinical only.
Because isobutylamides are studied almost exclusively as constituents of whole-plant preparations (particularly Echinacea), dosage data available from clinical research relates to the parent preparation, with isobutylamide content specified where standardization was employed.
No clinical dosage data exist for isolated isobutylamides administered as pure compounds in humans. Isobutylamide standardization per dose varies considerably across commercial products.
A total of 293 adverse events occurred with Echinacea and 306 with placebo treatment in one large RCT. Nine and 10% of participants experienced adverse events that were at least possibly related to the study drug (adverse drug reactions). Thus, the safety of Echinacea was noninferior to placebo.
The alkylamides are thought to be responsible for the immunomodulatory activity of Echinacea, and the concentration of 2E,4E,8Z,10E/Z-tetranoic acid isobutylamide and total alkylamide content were found to be associated with CYP 3A4 inhibitory potency. The chemically pure alkylamides dodeca-2E,4E,8Z,10E/Z-tetranoic acid isobutylamide and dodeca-2E,4E-dienoic acid isobutylamide showed inhibitory activity on CYP 2C19, 2D6 and 3A4. All tested Echinacea preparations were able to inhibit CYP 3A4, but inhibitory potencies (IC50) varied by a factor of 150. Importantly, these effects were observed in vitro, and potency is highly dependent on preparation and alkylamide concentration.
Neither Echinaforce nor the tested alkylamides produced any significant changes in the steady-state CYP3A4 mRNA levels under the tested conditions. In contrast, treatment with 50 μM rifampicin resulted in a 3.8-fold up-regulation over the vehicle control. The data conclude that Echinaforce is unlikely to affect CYP3A4 transcriptional levels, even at concentrations which can inhibit the enzymatic activity of CYP3A4. Overall, the data provides further evidence for the lack of clinically significant interactions between Echinacea and conventional drugs. A separate review similarly noted that an in vitro study showing the effects of an Echinacea preparation and isolated alkylamides on CYP3A4 expression did not document any statistically significant changes in the mRNA steady-state level of CYP3A4 after treating human hepatic cellular carcinoma HepG2 cells with clinically relevant concentrations of Echinaforce or any of the alkylamides.
Nine commercially available Echinacea preparations were screened for CYP3A4 inhibition. Their IC50 values varied by more than 50-fold, with the highest IC50 values obtained with E. purpurea expressed juice and the lowest with tinctures of E. purpurea and E. angustifolia. The total alkylamide content was positively associated with the ability of the preparations to inhibit CYP3A4. This indicates that the CYP3A4 inhibitory potential of an isobutylamide-containing product is proportional to its alkylamide content and preparation method.
In vivo studies suggest potential teratogenic effects with high doses of a hydroethanolic extract of A. oleracea. This finding is from animal models and has not been confirmed in humans, but represents a documented preclinical safety signal.
In the Ames test, neither the extract of H. longipes nor affinin induced mutations in the Salmonella typhimurium strains TA98 and TA100 or TA102 with or without the S9 microsomal fraction. This indicates no detected mutagenic potential in standard genotoxicity testing for affinin/spilanthol.
Echinacea belongs to the Asteraceae family. A case of painful lip swelling was reported in a 42-year-old man who presented to the emergency department following Spilanthes/Acmella exposure, illustrating that hypersensitivity reactions — consistent with known Asteraceae cross-reactivity — are documented in the literature, though rare.
Health conditions that Isobutylamides may help support.
Body systems that Isobutylamides may help support.
Go back